about
Clinical development of histone deacetylase inhibitors as anticancer agentsTumor targeting using anti-her2 immunoliposomes.Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.A novel assay for monitoring internalization of nanocarrier coupled antibodies.Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodiesCanine spontaneous glioma: a translational model system for convection-enhanced deliveryInvestigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenograftsLiposome-based approaches to overcome anticancer drug resistance.Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft modelDevelopment of ligand-targeted liposomes for cancer therapy.Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastineAnti-HER2 immunoliposomes for targeted therapy of human tumors.A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.Development of a highly stable and targetable nanoliposomal formulation of topotecan.Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging.Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides.
P50
Q28244438-662322D2-FEEA-41E4-85EF-4D7A168E6DAAQ30698442-3F540884-B32F-42CB-A0C3-C0ED82D805B3Q31104590-AE2A3556-E74B-4765-9395-59BC0B72E5ACQ33259109-3ECE5DBB-7D6C-4117-83E9-AFCD6C236536Q33284494-39883EB9-31AF-4857-8819-039602B6233AQ33289414-33D7BE32-51CF-4F72-B7E8-6FF9E12DE3A1Q33322420-245643DD-5C87-4BC4-A76E-6B79CE9D6BA6Q34133134-DA556E08-3DDC-42F8-94B1-66247CD85692Q35570265-9E2D7426-E7BD-4007-A0C2-6542C03B7A4CQ35595419-BCE1FECC-677B-4B92-A23C-8F74BD5AF914Q35800657-EC62D2D4-524A-40F6-9F2D-2D025A716361Q35842511-34629C11-5E9F-4C6A-8F8D-87747F8C448AQ36013320-1903C45D-1ECD-496F-8456-D6EE1259876AQ36212921-3B2416A3-8F22-471B-8FD4-921E420C2463Q36544122-298B3ACE-C984-4C9D-B6B2-A9F4F20F2601Q37113900-21CF22D0-C0E3-4C32-8545-8A1AE094EEE4Q37201370-D4C1178C-DD5A-4FC2-B05E-CB1A13465AA4Q37279686-8747E427-EF56-407C-89B6-872CB88B9AA9Q38340086-DD75E2A4-C007-4521-89EC-000916010E1EQ38958565-763236DE-2F79-493C-9112-F7E4414F6252Q39158242-1CA07F3D-BEE5-4DD2-8B17-73DA19634A0FQ39811573-09AFE68B-D7C3-4845-B658-676EE4CE0AD1Q39949287-BCDE273A-64AB-4C51-9D8F-62A368A79A9AQ40067406-302908A6-A75E-4AD2-A570-DE90566599B3Q40097009-832C2C72-E5DD-4632-B08A-730ECB59FE21Q40309769-C1DEA8A0-FA49-4CE1-8231-572F690A7A98Q40421390-950F243B-713F-4B17-BA29-41B4A4B97CC8Q40427954-8FA79356-A155-4111-BD83-73F0E2263B72Q40595415-D049240B-F4B5-4C64-8869-F4193164FB0BQ40829903-474432BA-4005-469B-A5F4-BAC80DF198ABQ44826956-72521482-87D0-4BF2-8ACA-2F85BCD6B9B3Q44918948-BD704AD7-2DE5-4CD9-A454-0FF3519FF540Q45889139-4DA61E6E-8A4A-4BE2-AA6B-06AD99C99EBDQ46002668-402537D0-CB20-4822-9B04-AFB5D9459D85Q46067245-5D1451AA-930A-421E-B14B-0E63BF161639Q46097998-35BB3CF8-4E6A-4C61-8591-18A2BF0ABEB4Q46498459-5044D648-80EA-4654-AF53-81650D2BA21FQ46537704-CE14C035-B11C-4834-BD44-2DDD28FF7602Q46832731-DCF9E7AC-7595-4A90-9240-F52FEE33CC11Q46877752-6F896241-DAEC-4960-823C-BEC41EFB5FAF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dmitri B. Kirpotin
@ast
Dmitri B. Kirpotin
@en
Dmitri B. Kirpotin
@es
Dmitri B. Kirpotin
@nl
Dmitri B. Kirpotin
@sl
type
label
Dmitri B. Kirpotin
@ast
Dmitri B. Kirpotin
@en
Dmitri B. Kirpotin
@es
Dmitri B. Kirpotin
@nl
Dmitri B. Kirpotin
@sl
prefLabel
Dmitri B. Kirpotin
@ast
Dmitri B. Kirpotin
@en
Dmitri B. Kirpotin
@es
Dmitri B. Kirpotin
@nl
Dmitri B. Kirpotin
@sl
P106
P1153
6701493838
P31
P496
0000-0002-1726-4040